<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20110802120603+02'00'</creation_date><modification_date>D:20110802120606+02'00'</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-03-269_h_dec_6.pdf</pdf_file></head><body><section><header>european commission brussels, 27.7.2011 c(2011)5592 final</header></section><section><header>commission implementing decision of 27.7.2011 
 amending the marketing authorisation for &quot;faslodex - fulvestrant&quot;, a medicinal 
 product for human use, granted by decision c(2004)851</header><p>(text with eea relevance) (only the english text is authentic)</p></section><section><header>commission implementing decision of 27.7.2011 
 amending the marketing authorisation for &quot;faslodex - fulvestrant&quot;, a medicinal 
 product for human use, granted by decision c(2004)851</header><p>(text with eea relevance) (only the english text is authentic) 
 the european commission, 
 having regard to the treaty on the functioning of the european union, 
 having regard to regulation (ec) no 726/2004 of the european parliament and of the 
 council of 31 march 2004 laying down community procedures for the authorisation and 
 supervision of medicinal products for human and veterinary use and establishing a 
 european medicines agency
 1, having regard to commission regulation (ec) no 1234/2008 of 24 november 2008 
 concerning the examination of variations to the terms of marketing authorisations for 
 medicinal products for human use and veterinary medicinal products
 2, and in particular article 17(2) thereof, 
 having regard to the application submitted on 24 april 2011 by astrazeneca uk limited 
 under article 16 of regulation (ec) no 1234/2008, 
 having regard to the notification submitted by astrazeneca uk limited, under the 
 second subparagraph of article 14(1) of regulation (ec) no 1234/2008, 
 having regard to the opinion(s) of the european medicines agency, formulated by the 
 committee for medicinal products for human use on 23 june 2011, 
 whereas: 
 (1)</p><p>the european medicines agency has informed the marketing authorisation 
 holder and the commission of its favourable opinion on the major variation type 
 ii and of the need to amend the marketing authorisation for the medicinal product 
 &quot;faslodex - fulvestrant&quot; which is entered in the community register of 
 medicinal products under numbers eu/1/03/269/001-002.</p><p>
 1 oj l 136, 30.4.2004, p. 1. 2 oj l 334, 12.12.2008, p. 7.</p><p> (2) the european medicines agency has informed the marketing authorisation 
 holder and the commission of its favourable opinion on a minor variation notified 
 between 8 december 2010 and 23 june 2011. 
 (3)</p><p>the marketing authorisation should be updated and decision c(2004)851 of 10 
 march 2004 should therefore be amended accordingly. the community register 
 of medicinal products should also be updated. 
 (4)</p><p>for the sake of clarity and transparency, it is advisable, following the amendment 
 of part or parts of the annexes, to provide for a consolidated version thereof. the 
 annexes to decision c(2004)851 should therefore be replaced, 
 has adopted this decision: 
 article 1 decision c(2004)851 is amended as follows: 1) the following notification for a minor variation is added to the marketing 
 authorisation: 
 application number 
 scope (eu numbers affected)</p><p>emea/h/c/540/ig/35 
 c.i.9.i) (eu/1/03/269/001-002)</p><p>
 2) annex i is replaced by the text set out in annex i to this decision;</p><p>3) annex ii is replaced by the text set out in annex ii to this decision;</p><p>4) annex iii b is replaced by the text set out in annex iii b to this decision. 
 article 2 this decision is addressed to astrazeneca uk limited, alderley park, macclesfield, cheshire, sk10 4tg united kingdom. 
 done at brussels, on 27.7.2011.</p><p>for the commission</p><p>
 paola testori coggi</p><p>
 director-general</p></section></body></xml>